口服抗凝期间发生缺血性卒中的房颤患者结局
本研究基于五项房颤抗血栓治疗关键随机试验的个体参与者数据,评估了研究药物(华法林、标准剂量或低剂量直接口服抗凝药方案)治疗期间发生随机化后缺血性卒中的患者结局。主要终点为首次随机化后缺血性卒中后的复发性缺血性卒中。中位继续随访337天,1年复发性缺血性卒中累积发生率为7.0%(95%CI 5.2%-8.7%),卒中后3个月死亡累积发生率为12.4%(95%CI 10.5%-14.4%)。结论认为,口服抗凝期间发生缺血性卒中的房颤患者复发卒中和死亡风险增加,存在未满足的医疗需求。
要点
- 口服抗凝期间发生缺血性卒中的房颤患者1年复发性缺血性卒中累积发生率为7.0%。
- 卒中后3个月死亡累积发生率为12.4%。
- 该类患者复发卒中和死亡风险增加,存在未满足的医疗需求。
核心结论
- 口服抗凝期间发生缺血性卒中的房颤患者复发缺血性卒中和死亡风险增加,目前存在未满足的医疗需求。
研究设计与样本
- 基于五项房颤抗血栓治疗关键随机试验的个体参与者数据,评估研究药物(华法林、标准剂量或低剂量直接口服抗凝药方案)治疗期间发生随机化后缺血性卒中的患者结局。
- 主要分析纳入1163例在研究药物期间发生首次随机化后缺血性卒中的患者,中位年龄73岁,女性39.3%,35.4%在试验入组前有卒中史。
主要发现
- 中位继续随访337天,74例患者发生复发性缺血性卒中,1年累积发生率为7.0%(95%CI 5.2%-8.7%)。
- 卒中后3个月死亡累积发生率为12.4%(95%CI 10.5%-14.4%)。
- 考虑死亡竞争风险的分析中1年复发性缺血性卒中发生率为6.2%(95%CI 4.8%-7.9%)。
- 排除索引卒中后前2周且仅纳入此后未永久停用研究药物的患者的界标分析中,1年复发性缺血性卒中发生率为6.8%(95%CI 4.6%-8.9%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The prognosis of patients with atrial fibrillation (AF) and ischemic stroke while taking oral anticoagulation is poorly understood. This study aimed to characterize the outcomes of patients following a stroke event while on oral anticoagulation. METHODS AND RESULTS: Individual participant data from five pivotal randomized trials of antithrombotic therapy in AF were used to assess the outcomes of patients with a post-randomization ischemic stroke while on study medication (warfarin, standard-, or lower-dose direct oral anticoagulant regimen) during trial follow-up. The primary outcome was recurrent ischemic stroke after the first post-randomization ischemic stroke. The primary analysis included 1163 patients with a first post-randomization ischemic stroke while on study medication (median age 73 years, 39.3% female, 35.4% history of stroke before trial enrollment). During a median continued follow-up of 337 days, 74 patients had a recurrent ischemic stroke [cumulative incidence at 1 year: 7.0%, 95% confidence interval (CI) 5.2%-8.7%]. The cumulative incidence of mortality at 3 months after stroke was 12.4% (95% CI 10.5%-14.4%). Consistent results for the incidence of recurrent ischemic stroke at 1 year were obtained in an analysis accounting for the competing risk of death (6.2%, 95% CI 4.8%-7.9%) and in a landmark analysis excluding the first 2 weeks after the index stroke and only including patients without permanent study drug discontinuation since then (6.8%, 95% CI 4.6%-8.9%). CONCLUSION: Patients with AF and ischemic stroke while on oral anticoagulation are at increased risk of recurrent ischemic stroke and death. These patients currently have an unmet medical need.
引用
- Benz, Hohnloser, Eikelboom, et al. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. Eur Heart J. 2023. PMID: 37038327. doi:10.1093/eurheartj/ehad200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。